Olanzapine is an atypical antipsychotic widely used for the treatment of schizophrenia,
which often causes serious adverse drug reactions. Currently, there are no clinical …

Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is
associated with alterations in safety and efficacy. The aim of this systematic review is to …

Objective The pharmacokinetics of olanzapine and response to treatment could be affected
by polymorphisms in genes coding for drug‐metabolizing enzymes, transporters, or …

The pharmacokinetics of the atypical antipsychotic, olanzapine, display large interindividual
variation leading to multiple-fold differences in drug exposure between patients at a given …

Olanzapine is a commonly prescribed atypical antipsychotic agent for treatment of patients
with schizophrenia and bipolar disorders. Previous in vitro studies using human liver …

Objective Metabolism of the atypical antipsychotic olanzapine (OLA) is partially catalyzed by
cytochrome P450 (CYP) 1A2, a target of aryl hydrocarbon receptor (AHR)-mediated …

Background: Although several polymorphisms in olanzapine-metabolizing enzymes have
been identified, the clear role and benefit for pharmacotherapy remain uncertain. The aim of …

The antipsychotic drug, olanzapine, one of the most widely used drugs in clinical medicine,
has a high rate of discontinuation due to inefficacy and/or adverse effects. We identified a …

Objective: Limited data suggest that CYP1A2 and CYP2D6 are involved in the metabolism of
olanzapine. The purpose of this study was to further elucidate the role of these enzymes in …

Clinical use of the a olanzapine has significantly different individual-to-individual outcomes.
Accordingly, this study aimed to develop a means of predicting response to olanzapine …